期刊文献+

伊贝沙坦对胰岛素抵抗大鼠肾间质纤维化的影响

下载PDF
导出
摘要 目的:观察伊贝沙坦对胰岛素抵抗大鼠肾组织中基质金属蛋白酶-2(MMP-2)、天然抑制物金属蛋白酶组织抑制剂-1(TIMP-1)的影响与肾间质纤维化的关系。评价伊贝沙坦对肾间质纤维化的治疗作用。方法:将大鼠随机分为对照组、高果糖喂养组和伊贝沙坦干预组,每组8只。每周测血压1次,喂养18周后处死取血检测空腹血糖(FBG)、胰岛素(FINS),并取肾组织进行常规肾脏病理检查,肾组织免疫组织化学染色对肾组织MMP-2、TIMP-1图像分析定量测定。结果:各组大鼠血糖之间无统计学差异(P>0.05)。对照组与伊贝沙坦组空腹胰岛素无差异(P>0.05),而高果糖喂养组胰岛素水平显著高于其他两组(P<0.05)。高果糖喂养组胰岛素敏感性明显低于对照组和伊贝沙坦组(P<0.01)。伊贝沙坦组较高果糖喂养大鼠肾组织MMP-2明显升高、TIMP-1明显降低和MMP-2/TIMP-1明显升高(P<0.01)。结论:伊贝沙坦可改善高果糖喂养大鼠的胰岛素抵抗。高果糖喂养可以降低肾组织MMP-2,提高TIMP-1,降低MMP-2/TIMP-1,而伊贝沙坦可逆转这种改变。
出处 《中国中西医结合肾病杂志》 2008年第3期244-246,I0004,共4页 Chinese Journal of Integrated Traditional and Western Nephrology
基金 河北省卫生厅医学科学研究重点指导项目(No07169)
  • 相关文献

参考文献14

  • 1Bumier M, Brurmer HR. Angiotensin Ⅱ receptor antagonists. Lancet, 2000,355 (9204) : 637 - 645.
  • 2Kim S, Iwao H. Molecular and cellular mechanism of angiotensin Ⅱ- mediated cardiovascular and renaldisease. Pharmacology Rev, 2000,52(1) : 11 - 34.
  • 3Cooper ME, Webb RL, de Gasparo M. Angiotensin Ⅱ receptor blockers and the kidney: possible advantagesover ACE inhibition? Cardiovas Drug Rev, 2001,19 (1) : 75 - 86.
  • 4Higashiura K, Ura N, Takada T, et al. The effects of an angiotensin- converting enzyme inhibitor and an angiotensin Ⅱ receptor antagonist on insulin resistance in fructose - fed rats. Am J Hypertens,2000,13(3) :290 - 297.
  • 5刘必成,罗冬冬,张晓良,孙子林,马坤岭,周秋根.伊贝沙坦对链脲佐菌素诱导的糖尿病大鼠肾脏肥大的影响[J].中国病理生理杂志,2004,20(11):2086-2089. 被引量:11
  • 6Grinsell JW, Lardinois CK, Swislocki A, et al. Pioglitazone attenuates basal and postprandial insulin concentrations and blood pressure in the spontaneously hypertensive rat. Am J Hypertension, 2000,13 (4 Pt 1 ):370 - 375.
  • 7Onodera T, Tamura T, Suleman S, et al. Maladaptive remodeling of cardiac myocyte shape begins long before failure in hypertension. Hypertension, 1998,32(4) :753 - 757
  • 8Kim S, Yoshiyama M, Izumi Y, et al. Effects of combination of ACE inhibitor and angiotensin receptor blocker on cardiac remodling, cardiac function, and survival in rat heart failure. Circulation, 2001,103 (1) : 148 - 154.
  • 9李光伟.当前胰岛素敏感性评估及胰岛素抵抗研究中的某些误区[J].中华内科杂志,1998,37(2):81-83. 被引量:90
  • 10Eikmans M, Baelde HJ, de Heer E, et al. RNA expression profiling as prognostic tool in renal patients: toward nephrogenomics. Kidney Int,2002,62(4) : 1125 - 1135.

二级参考文献18

  • 1张家庆,中华内分泌代谢杂志,1997年,13卷,77页
  • 2李光伟,中华心血管病杂志,1996年,24卷,57页
  • 3Ziyadeh EF. The extracellular matrix in diabetic nephropathy[J]. Am J Kidney Dis, 1993, 22(5): 736-744.
  • 4Leehey DJ, Singh AK, Alavi N, et al. Role of angiotensin II in diabetic nephropathy[J]. Kidney Int, 2000, 58(Suppl 77): S93-S98.
  • 5Cao Z, Bonnet F, Davis B, et al. Additive hypotensive and anti-albuminuric effects of angiotensin-converting enzyme inhibition and angiotensin receptor antagonism in diabetic spontaneously hypertensive rats[J]. Clin Sci, 2001, 100(6): 591-599.
  • 6Keane WF, Lyle PA. Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENNAL study[J]. Am J Kidney Dis, 2003, 41(3 Suppl 2):S22-S25.
  • 7Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes[J]. N Engl J Med, 2001, 345 (12):851-860.
  • 8Thulesen J, Poulsen SS, Jorgensen PE ,et al. Adrenergic blockade in diabetic and uninephrectomized rats: effects on renal size and on renal and urinary contents of epidermal growth factor[J]. Nephron, 1999, 81(2):172-182.
  • 9Wolf G, Ziyadeh FN. Molecular mechanisms of diabetic renal hypertrophy[J]. Kidney Int, 1999, 56 (2): 393-405.
  • 10Rossert J, Terraz-Durasnel C, Brideau G. Growth factors, cytokines, and renal fibrosis during the course of diabetic nephropathy[J]. Diabetes Metab, 2000, 26(Suppl 4): 16-24.

共引文献97

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部